Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel α-Klotho Protein Therapy
Innovative Modified Soluble α-Klotho Protein Shows Promise for Treating the $16B Chronic Kidney Disease and Phosphate Metabolism Disorders Markets Boston, AM – October 14, 2025 – Anzor Pharmaceuticals is pleased to announce the issuance of U.S. Patent No. 12,227,777 B2 for a novel modified soluble α-Klotho protein with enhanced therapeutic properties. This breakthrough technology represents […]
Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia (XLH)
FDA Orphan Drug Designation offers Anzor key development incentives and seven years of market exclusivity, enhancing the therapy’s commercial potential. Boston, MA – July 24, 2025 – Anzor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead investigational therapy, a novel FGF23 peptide antagonist, for […]
Anzor Pharmaceuticals Selected to Present at the Prestigious BioLabs-NYU Investor & Innovator Exchange
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES Boston, MA – May 6, 2025 – Anzor Pharmaceuticals is honored to announce its selection as a presenting company at the 2025 BioLabs-NYU Investor & Innovator Exchange, taking place on May 6, 2025, in New York City. This high-profile event, now in its second year, […]
Anzor Pharmaceuticals to Present at Chronic Kidney Disease Conference
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES BOSTON, March 19, 2025 – Anzor Pharmaceuticals, a leader in the development of targeted fibroblast growth factor (FGF) peptide therapy, today announced that Christopher P Adams, CEO will present at the 7th Annual Chronic Kidney Disease Conference in Boston Massachusetts on March 19, 2025. […]
